RECIPIENT & INSTITUTION
Identifying novel mechanisms of androgen-mediated growth control as new
targets for intervention and prognostic biomarkers in prostate cancer (PG12-34)
Targeting ABC transporter autocrine loop in prostate cancer (PG12-23)
Enhancement of targeted radiotherapy for prostate cancer using PSMA-seeking
agents in combination with radiosensitisers (PG12-12)
Investigating the regulation and effects on androgen receptor expression using
culture models of castration resistant prostate cancer that induce embryonic stem
Advanced prostate cancer: does targeting hypoxic cel s block malignant
Quantitative shear wave elastosonography in the detection and characterisation
Evaluating synergy between deregulation of the PI3-kinase,
Wnt and Ras pathways in prostate neoplasia (PG12-16)
Using circulating plasma DNA as a multi-purpose biomarker to identify
aggressive prostate cancer and mechanisms of drug resistance (PG12-49)
Development of a first-in-class preclinical drug candidate for the treatment of
castrate-resistant prostate cancer (PG12-27)
Developing a new targeted therapy for treatment of metastatic prostate cancer:
synthesis and preclinical validation of sphingosine kinase inhibitor-docetaxel
Targeting the tumour-initiating population in prostate cancer
Imaging avb3 integrin expression in skeletal metastases from prostate cancer
with 99mTc-maraciclatide single photon emission computed tomography
(SPECT): staging and therapy monitoring (PA12-04)
Development of a novel cytotopic immunotherapeutic cocktail for targeted
treatment of advanced prostate cancer (PA12-01)
Role of Receptor Activity Modifying Protein-3 in regulation of lysyl oxidase-2
Prostate cancer immunotherapy using genetical y targeted T-cel s, guided by
a stromal-specific immunocytokine (PA12-06)
Prostate cancer response assessment and treatment stratification through
circulating free tumour DNA detection (PA12-15)
Therapeutic inhibition of the Histone Demethylase LSD1 to attenuate androgen
receptor signal ing in prostate cancer (PG12-03)
The use of a novel technology platform to create a DNA vaccine for
Role of stroma microenvironments in prostate cancer cell migration
Development of a transcriptional repressor based approach for the treatment
Aldehyde dehydrogenases in prostate cancer (S12-027)
RECIPIENT & INSTITUTION
The FAS/AMPK axis as a determinant of prostate cancer progression (S12-008)
Identification and validation of novel therapeutic targets in prostate cancer by
investigating the cell kil ing mechanisms of the oncolytic adenovirus Ad
in combination with cytotoxic drugs (S12-021)
Characterising novel phosphatase enzymes important in regulating
androgen receptor function in the progression of castrate
Influence of stage and therapy on the NKG2D axis in prostate cancer
Development of tumour-selective therapeutics for advanced
Synergistic interaction between Sprouty2 loss and PI3K/AKT activation
Beatson Institute, University of Glasgow
The role of IKKa and IKKb in prostate cancer progression
A new approach to evaluating prostate cancer diagnostic markers in men
with a raised PSA undergoing template mapping biopsy
Improving Prostate Cancer Diagnosis and Monitoring using
Development of dual β3 integrin antagonists as a novel anti-metastatic
therapeutic for castration-resistant prostate cancer
The role of autophagy in the initiation, progression and recurrence
Targeting AMACR to treat castrate-resistant prostate cancer
Optimal radiation targeting of PTEN deficiency in castrate resistant
prostate cancer in combination with modulators of DNA damage
The androgen receptor amino-terminal domain: a novel drug target
for the treatment of castrate resistant prostate cancer
Development and evaluation of a guided self-help intervention to
al eviate hormone treatment side effects (hot flushes and night sweats)
A pilot randomized controlled trial of a nurse-led psycho-educational
intervention delivered in primary care to prostate cancer survivors
Role of the endogenous signal ing regulator Similar Expression
to FGF (Sef) in growth factor signal ing in prostate cancer
Mouse modeling of prostate cancer through TMP-ETS family
The role of ubiquitin in androgen receptor function in prostate cancer
A novel chemoprotective role for vitamin D in prostate cancer
Exploiting defects in DNA repair for treatment of prostate cancer
RECIPIENT & INSTITUTION
A Phase Ib/II trial of Prostate Radiotherapy in Conjunction with Carbogen
Living with and beyond Prostate Cancer: Does more investigation result
in better health? A study of the impact on men of increased and variable
investigation and treatment of prostate cancer in the Island of Ireland
The public face of prostate cancer in the UK
A new approach to delivery of super-potent drugs to prostate tumours
Trial of devices for intractable urinary incontinence fol owing prostate
Identifying mechanisms of resistance to specific CYP17 inhibition with
Novel proteomic approach combined with an RNAi screen to identify
Sphingosine kinase-1 signal ing during prostate cancer cel motility,
Understanding prostate tumour response to bicalutamide can lead
DNA damage response in prostate cancer stem cel s
A mechanism-based system of classification for human prostate cancer
Analysis of stromal signaling pathways in human prostate cancer initiation
The use of nitric oxide in combination with radiotherapy as a new treatment
for prostate cancer found under low oxygen conditions
1. THE HORSE / PONY If looking at purchasing horses / ponies with the intention of showing, the main things to consider are confirmation, movement, attitude and presence. Take your time and do your home work if purchasing a horse/pony for a specific discipline. Where possible, go to as many events as you can as a spectator, and visit as many studs as possible. The right choice can make all the dif
MASTER GARDNER INTERNATIONAL CONFERENCE Sponsored by The University of California, Davis DYNAMIC GROWING FOR MASTER GARDENERS WILLIAM R. JACKSON, PhD Author, Consultant, Educator This concise synopsis was made available to the Master Gardeners International for its Conference July 15-19, 1997, in Sacramento, California. At the time of this presentation on July 16, the audience s